DNTH · ISSUER CIK 1690585
Dianthus Therapeutics, Inc. /DE/
Between Aug 1, 2026 and Oct 29, 2026, 6 Dianthus Therapeutics, Inc. /DE/ insiders reported $0.00 of open-market purchases and $26.1M of sales on SEC Form 4.
↗6 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 7 of 7 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$26.1MInsider selling
−$26.1MNet open-market
Sep 18, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 202616:36 | Sep 17, 2026 | DNTH | CHIEF ACCOUNTING OFFICER | S · Sell10b5-1 | $101.38 | −20,000 | 0 | -100% | −$2.0M | ||
| Sep 18, 202616:36 | Sep 17, 2026 | DNTH | CHIEF ACCOUNTING OFFICER | M · Exercise10b5-1 | $17.88 | +20,000 | 20,000 | New | $358K | ||
| Sep 3, 202616:30 | Sep 1, 2026 | DNTH | EVP, Head of R&D | S · Sell10b5-1 | $106.41 | −23,124 | 4,000 | -85% | −$2.5M | ||
| Sep 3, 202616:30 | Sep 1, 2026 | DNTH | EVP, Head of R&D | M · Exercise10b5-1 | $20.63 | +23,124 | 27,124 | +578% | $477K | ||
| Aug 19, 202618:02 | Aug 19, 2026 | DNTH | Director | S · Sell10b5-1 | $117.55 | −2,778 | 0 | -100% | −$327K | ||
| Aug 19, 202618:02 | Aug 19, 2026 | DNTH | Director | M · Exercise10b5-1 | $18.36 | +2,778 | 2,778 | New | $51K | ||
| Aug 14, 202616:30 | Aug 13, 2026 | DNTH | SVP, General Counsel and Sec. | M · Exercise | $18.17 | +15,000 | 15,000 | New | $273K | ||
| Aug 11, 202617:15 | Aug 10, 2026 | DNTH | Director | S · Sell10b5-1 | $109.01 | −7,750 | 0 | -100% | −$845K | ||
| Aug 11, 202617:15 | Aug 10, 2026 | DNTH | Director | M · Exercise10b5-1 | $12.52 | +7,750 | 7,750 | New | $97K | ||
| Aug 11, 202617:10 | Aug 10, 2026 | DNTH | Director | S · Sell10b5-1 | $109.55 | −2,777 | 0 | -100% | −$304K | ||
| Aug 11, 202617:10 | Aug 10, 2026 | DNTH | Director | M · Exercise10b5-1 | $18.36 | +2,777 | 2,777 | New | $51K | ||
| Aug 11, 202617:08 | Aug 10, 2026from Aug 7, 2026 | DNTH | SVP, General Counsel and Sec. | S · Sell10b5-1 | $110.44 | −20,000 | 0 | -100% | −$2.2M | ||
| Aug 11, 202617:08 | Aug 10, 2026from Aug 7, 2026 | DNTH | SVP, General Counsel and Sec. | M · Exercise10b5-1 | $17.88 | +20,000 | 16,167 | — | $358K | ||
| Aug 7, 202618:30 | Aug 7, 2026 | DNTH | CEO AND PRESIDENT, Director | S · Sell10b5-1 | $108.11 | −166,000 | 65,292 | -72% | −$17.9M | ||
| Aug 7, 202618:30 | Aug 7, 2026 | DNTH | CEO AND PRESIDENT, Director | M · Exercise10b5-1 | $8.44 | +166,000 | 231,292 | +254% | $1.4M |